The role of cell cycle regulatory proteins, cyclin D1, cyclin E, and p27 in thyroid carcinogenesis

Human Pathology

Volumn 29, Issue 11, 1998, Pages 1304-1309

  Wang, Songtao ^a   Wuu, Joanne ^a   Savas, Lou ^a   Patwardhan, Nilima ^a   Khan, Ashraf ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Cyclins; Follicular adenoma; Follicular variant papillary carcinoma; P27

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN E; PROTEIN P27;

ADENOMA; ARTICLE; CARCINOGENESIS; CELL CYCLE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; PAPILLARY CARCINOMA; PHOSPHORYLATION; PROTEIN EXPRESSION; THYROID CANCER;

EID: 0031788262     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(98)90262-3     Document Type: Article

References (49)

1. Dirks PB, Rutka JT: Current concepts in neuro-oncology: The cell cycle: A review. Neurosurgery 40:1000-1015, 1997
2. Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149-1163, 1995
3. Hall M, Peter G: Genetic alterations of cyclins, cyclin-dependent kinases, and cdk inhibitors in human cancers. Adv Cancer Res 68:67-108, 1996
4. Wang J, Cheniress X, Henglein B, et al: Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature 343:555-557, 1990
5. Quelle DE, Ashman RA, Shurleff SA, et al: Overexpression of mouse D-type cyclins accelerates G1 phases in rodent fibroblasts. Genes Dev 7:1559-1591, 1993
6. Motokura T, Bloom T, Kim HG, et al: A novel cyclin encoded by a bcl-1 linked candidate gene. Nature 350:512-515, 1991
7. Matsushine H, Roussel MF, Ashman RA, et al: Colony-stimulating factor I regulates cyclins during the G1 phase of cell cycle. Cell 65:701-713, 1991
8. Withers DA, Harvey RC, Faust JB, et al: Characterization of a candidate bcl-1 gene. Mol Cell Biol 11:4846-4853, 1991
9. Bartkova J, Lukas J, Strauss M, et al: Cyclin D1 oncoprotein accumulates in malignancies of diverse histogenesis. Oncogene 10:775-778, 1993
10. Buckley MF, Sweeney KJ, Hamilton JA, et al: Expression and amplification of cyclin genes in human breast cancer. Oncogene 8:2127-2133, 1993
11. Jares P, Fernandez PL, Campo E, et al: PRAD1/cyclin D1 gene amplification correlates with mRNA overexpression and tumor progression in human laryngeal carcinomas. Cancer Res 54:4813-4817, 1994
12. Jiang W, Kahn SM, Tomita N, et al: Amplification and expression of human cyclin D gene in esophageal cancer. Cancer Res 52:2980-2983, 1992
13. Lukas J, Muller H, Bartkova J, et al: DNA tumor virus proteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement of cyclin D1 function in G1. J Cell Biol 125:625-638, 1994
14. Michalides R, van Veelen N, Hart A, et al: Overexpression of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 55:975-978, 1995
15. Moran E: DNA tumor virus transforming proteins and the cell cycle. Curr Opin Genet Dev 3:63-70, 1993
16. Leach FS, Elledge SJ, Sherr CJ, et al: Amplification of cyclin genes in colorectal carcinoma. Cancer Res 53:1986-1989, 1993
17. Keyomarsi K, O'Leary N, Molnar G, et al: Cyclin E: A potential prognostic marker for breast cancer. Cancer Res 54:380-385, 1994
18. kip1, a cyclin-cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Rev 8:9-22, 1994
19. kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59-66, 1994
20. El-Deiry WS, Tokino T, Velculescu VE, et al: WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993
21. Xiong Y, Hannon GT, Zhang H, et al: p21, a universal inhibitor of cyclin kinase. Nature 366:701-704, 1993
22. Toyoshima H, Hunter T: p27, a novel inhibitor of G1 cyclin/cdk protein kinase activity, is related to p21. Cell 78:67-74, 1994
23. kip1 the cdk inhibitor family, is a candidate tumor supresser gene. Genes Rev 9:650-682, 1995
24. kip2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Rev 9:639-649, 1995
25. Kawamata N, Morosetti R, Miller CW, et al: Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 55:2266-2269, 1995
26. kip1 gene to 12p13 and its analysis in leukemias. Cancer Rev 55:1206-1210, 1995
27. Spirin KS, Simpson JF, Takeuchi S, et al: p27/kip1 mutation found in breast cancer. Cancer Res 56:2400-2404, 1996
28. Loda M, Cukor B, Tam SW, et al: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med 3:231-234, 1997
29. kip1 display increased body size, multiple organ hyperplasia, retina dysplasia, and pituitary tumors. Cell 85:707-721, 1996
30. kip1. Cell 85:721-732, 1996
31. kip1-deficient mice. Cell 85:733-744, 1996
32. kip1 in endocrine and other tumors. Am J Pathol 150:401-407, 1997
33. Rosai J: Ackerman's Surgical Pathology (ed 8). St Louis, MO, Mosby-Year Book, 1996
34. Armitage P, Berry G: Statistical Methods in Medical Research (ed 3). Oxford, England, Blackball Science Ltd, 1994
35. Zhang S-Y, Caamano J, Cooper F, et al: Immunohistochemistry of cyclin D1 in human breast cancer. Am J Clin Pathol 102:695-698, 1994
36. Musgrove EA, Hamilton JA, Lee CSL, et al: Growth factor, steroid and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 13:3577-3587, 1993
37. Zukerberg LR, Yang W-I, Gadd M, et al: Cyclin D1 (PRAD1) protein expression in breast cancer: Approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. Mod Pathol 8:560-567, 1995
38. Fagin JA, Matssuto K, Karmakar A, et al: High prevalence of mutation of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179-184, 1993
39. Ito T, Seyama T, Mizuno T, et al: Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 52:1369-1371, 1992
40. Nakamura T, Yana I, Kobayashi T, et al: p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Jpn J Cancer Res 83:1293-1298, 1992
41. Tacheuchi S, Bartram CR, Seriu T, et al: Allelotype of acute lymphoblastic leukemia (ALL) identifies sites of tumor supresser genes. Blood 84:149a, 1994 (suppl 1)
42. Sato Y, Suto Y, Pietenpol J, et al: TEL and Kip1 define the smallest region of deletion s on 12p13 in hematopoietic malignancies. Blood 86:1525-1533, 1995
43. Wlodarska I, Mecucci C, Marynen P, et al: TEL gene is involved in myelodysplastic syndromes with either the typical t(5; 12)(q13;q11) translocation or its variant t(10;12) (q24;p13). Blood 85:2848-2852, 1995
44. Sawyers CL, Denny CT: Chronic myelomonocytic leukemia: Tel-a-kinase what Ets all about. Cell 77:171-173, 1994
45. Chen J, Willingham T, Shuford M, et al: Tumor suppression and inhibition of aneuploid cell accumulation in human brain tumor cells by ectopic overexpression of the cyclin-dependent kinase inhibitor. J Clin Invest 97:1983-1987, 1996
46. Hengst L, Dulic V, Slingerland J, et al: A cell cycle regulated inhibitor of cyclin-dependent kinases. Proc Nad Acad Sci USA 91:5291-5295, 1994
47. kip1 accumulation during cell cycle. Science 271:1861-1864, 1996
48. Coats S, Flanagan M, Nourse J, et al: Requirement of for restriction point control of the fibroblast cell cycle. Science 272:877-880, 1996
49. Lee M-H, Nikolic M, Baptista CA, et al: The brain specific activator p35 allows CDK 5 to escape inhibition by in neurons. Proc Natl Acad Sci U S A 93:3259-3263, 1996